Dianthus Therapeutics
Clinical-stage biotechnology company developing precision antibody therapeutics targeting the complement system for severe autoimmune and inflammatory diseases.
Notes
Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing precision antibody therapeutics targeting the complement system. The complement system is part of the innate immune system and plays a role in various autoimmune and inflammatory diseases.
The company was created through a merger between Dianthus and Magenta Therapeutics' autoimmune disease program. Dianthus is developing DNTH103, a monoclonal antibody targeting C5aR1 (complement component 5a receptor 1), for the treatment of severe autoimmune diseases.
Dianthus is publicly traded on NASDAQ under the ticker symbol DNTH.
Team
- Matthew Gline - CEO
- Leadership team available on company website
Additional Research Findings
- Portfolio company of Bain Capital Life Sciences
- Founded in 2021
- Publicly traded: NASDAQ (DNTH)
- Merged with Magenta Therapeutics autoimmune program in 2023
- Lead candidate: DNTH103 targeting C5aR1
- Focus on complement-mediated autoimmune diseases
- Target indications include myasthenia gravis and other complement-mediated conditions
- Headquarters in New York City